Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study

CONCLUSIONS: Using an exploratory patient-reported outcome measure, patients with MDD and inadequate response to antidepressants who received open-label adjunctive brexpiprazole showed early and clinically meaningful improvement in patient life engagement, which should be further assessed in a prospective randomized controlled trial. Patient-rated depressive symptoms (on the validated 30-item IDS-SR) also improved. Adjunctive brexpiprazole was well tolerated, and no new safety signals were observed.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04830215.PMID:38425284 | DOI:10.1177/07067437241233965
Source: Canadian Journal of Psychiatry - Category: Psychiatry Authors: Source Type: research